Cyclophosphamide and Fludarabine

Phase 1Small molecule

Cyclophosphamide and Fludarabine is one of 2 small molecule programs targeting Inflammatory Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory DiseaseRecruiting

Inflammatory DiseasePhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Inflammatory Disease

#DrugCompanyPhaseTrials

Jyseleca

Gilead

Phase 2

1 2

Cyclophosphamide and Fludarabine

TTongji Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Inflammatory Disease

NCT04561557

Clinical

Trials by Indication[1]

Inflammatory Disease1 trial

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Recruiting·TTongji Hospital·Phase 1·NCT04561557·36 enrolled

Advanced NSCLC1 trial

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Unknown status·GGuangzhou Institute of Respiratory Disease·Phase 1·NCT03029273·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cyclophosphamide and Fludarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclophosphamide and Fludarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclophosphamide and Fludarabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTongji Hospital

Cyclophosphamide and Fludarabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Inflammatory Disease1 trial

Advanced NSCLC1 trial

References

Drug Info

Quick Facts

Related News